CADL

Announcements

Nothing here yet

Daily updates

• Candel Therapeutics published peer-reviewed Phase 2a data for aglatimagene besadenovec plus valacyclovir in checkpoint inhibitor-refractory NSCLC, showing median overall survival of 24.5 months overall and 25.4 months in non-squamous disease, with immune activation and favorable tolerability. The results support the Phase 3 AURORA trial versus docetaxel in metastatic non-squamous NSCLC.Oct 2, 2026

FDA designations

• Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic CancerJul 24, 2025

News

• Candel Therapeutics publishes Phase 2a data showing prolonged survival after systemic immune reactivation with aglatimagene besadenovec plus valacyclovir in unresectable Stage III/IV NSCLC with inadequate ICI responseOct 2, 2026
• Candel Therapeutics publishes Phase 2a data showing prolonged survival after systemic immune reactivation with aglatimagene besadenovec plus valacyclovir in unresectable Stage III/IV NSCLC with inadequate ICI responseOct 1, 2026
• Candel Therapeutics reports integrated clinical and biomarker data showing durable local and systemic immune activation after aglatimagene besadenovec in intermediate-risk localized prostate cancerSep 30, 2026
• Candel Therapeutics presents new ASTRO 2026 data showing sustained immune remodeling more than two years after aglatimagene besadenovec treatment in localized prostate cancerSep 30, 2026
• Candel Therapeutics signed a commercialization agreement with EVERSANA to support the potential U.S. launch of Aglatimagene Besadenovec in localized prostate cancerApr 29, 2026